Business Context and Reporting Period
Company: iBio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 27, 2010
Event: Completion of a private offering of securities and entry into material definitive agreements.
Key Financial Metrics and Transaction Details
- Securities Issued: 3,032,500 shares of common stock.
- Purchase Price: $2.00 per share.
- Warrants Issued: Five-year warrants to purchase an equal number of shares (3,032,500) at an exercise price of $2.20 per share.
- Net Proceeds: Approximately $5,630,000.
- Placement Agent Fees: 7% cash fee of gross proceeds plus a five-year warrant to purchase 196,551 shares at $2.16 per share.
- Offering Status: Minimum offering closed; offering continues until November 26, 2010, with a target range of $6,000,000 to $8,000,000.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement and a Registration Rights Agreement. Under the Registration Rights Agreement, iBio, Inc. agreed to file a shelf registration statement within 30 days of the closing to allow investors to resell the shares and underlying warrants. The Company must use reasonable best efforts to keep this registration effective until all shares are sold or Rule 144 restrictions are lifted.
Outlook, Risks, and Unusual Items
- Registration Risk: The common stock and warrants were issued under Section 4(2) and Regulation D exemptions and are not registered. They cannot be resold in the U.S. without an effective registration statement or another exemption.
- Continuing Offering: The offering remains open until November 26, 2010, to reach the maximum target of $8,000,000.
- Disclosure Timing: Full texts of definitive agreements will be filed in the next Quarterly Report on Form 10-Q.
Investor Verification Checklist
- Verify the final total proceeds once the offering closes on November 26, 2010.
- Confirm the filing and effectiveness of the shelf registration statement within the 30-day and 90-day windows specified in the agreement.
- Review the upcoming Form 10-Q for the full text of the Securities Purchase Agreement and Placement Agent Agreement.
- Monitor the dilution impact of the 3,032,500 new shares and the associated warrants.